RxDoctor Payments Data

Rouba Ghoussoub, MD

Nephrology · Belleville, ILNPI 1396964599

Payments from drug & device makers

$2,548in general payments, 2019–2025

Across 106 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nxstage Medical, Inc.$221
  • Fresenius USA Marketing, Inc.$173
  • AstraZeneca$172
  • Mallinckrodt Hospital Products Inc.$171
  • Boehringer Ingelheim$160
  • Vifor Pharma, Inc.$153
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,42895%
  • Education$1195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,548 in reported general payments places this provider in the 70th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$106,459
Medicare patients
365
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide55$147,713
JardianceEmpagliflozin72$74,123
FarxigaDapagliflozin Propanediol29$29,683
Mycophenolate Mofetil12$22,952
Lanthanum Carbonate11$19,017
LokelmaSodium Zirconium Cyclosilicate14$13,594
VeltassaPatiromer Calcium Sorbitex13$10,977
Sevelamer Carbonate41$6,681
Calcitriol197$2,345
Tacrolimus11$1,870
Losartan Potassium208$1,413
Doxazosin Mesylate107$1,047
Amlodipine Besylate163$849
Spironolactone86$822
Lisinopril114$810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$173$147,71355 claims
Boehringer IngelheimJardiance$160$74,12372 claims
AstraZenecaFarxiga, Lokelma$172$43,27843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 524 nephrology providers in Illinois.

Other nephrology in Belleville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →